Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (September 2021)
22 slides from Cantargia Ab's investor presentation, Sep 28, 2021
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO September 2021
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: I. Introduction
I. INTRODUCTION
Slide 4: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value Type of Discovery Preclinical Clinical Clinical Clinical Commercial Project Disease treatment phase phase Phase I Phase II Phase III phase Gemcitabine/nab-paclitaxel ➢ Potentially more effective Pancreatic cancer 1st line treatment against novel
Slide 5: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors Current owners (30 Jun 2021) • Positive clinical interim data and further results during 2021 Swedbank Robur Funds 9.7% VISION OF BECOMING AN IMPORTA
Slide 6: II. Lead antibody nadunolimab (CAN04)
II. LEAD ANTIBODY NADUNOLIMAB (CAN04)
Slide 7: CAN04 – Mechanism of action
CAN04 – Mechanism of action ADCC – Reduced activation Reduced Tumor cell death and infiltration of angiogenesis immunosuppressive cells CAN04 BLOCKS BOTH FORMS OF IL-1 AND CAN ERADICATE CELLS MEDIATING THE EFFECTS OF IL-1 Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated
Slide 8: CAN04 – Differentiated and superior MOA
CAN04 – Differentiated and superior MOA Cancer context IL-1α IL-1β comment Localization • Cellbound and soluble • Soluble • IL-1α trigger and IL-1β • Cancer cells and stroma enhance inflammation • Often work in pair Function • Stimulates inflammation - IL1R1 -forming complex with IL1RAP • No known d
Slide 9: CAN04 broad mechanism uniquely enhance docetaxel antitumor activity
CAN04 broad mechanism uniquely enhance docetaxel antitumor activity ✱ 100 Tumor growth (%) → CAN04 in combination with docetaxel in MC38 syngeneic model → CAN04 increase efficacy of docetaxel 50 → Control antibody blocking IL-1β did not have the same effect → In vitro experiment show docetaxel incre
Slide 10: Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)
Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020) → Upregulation of both forms of IL-1 in PDX-model as response to Gem/Cis → IL-1α (DAMP) on cancer cells trigger inflammasome activation in tumor microenvironment (e.g. IL-1β) → CAN04 increases efficacy of Pt based chemo
Slide 11: Combination data in NSCLC show promising efficacy
Combination data in NSCLC show promising efficacy → CAN04 in combination with gem/cis in 1st line chemotherapy → 13* of 27 evaluable patients with non-sq non-small cell lung cancer (NSCLC) showed objective response including 1 complete response (48% vs historical control data 22-28%) → No major side
Slide 12: Strong signal in non-squamous NSCLC
Strong signal in non-squamous NSCLC Non-squamous 50 → CAN04 in combination with gem/cis in 1st line chemotherapy Percent tumor reduction Stable disease * * * * * * * Partial response → 8 of 15 evaluable patients with non-sq non-small cell lung 0 * (RECIST 1.1) Complete response cancer (NSCLC) showed
Slide 13: Positive data in pancreatic cancer
Positive data in pancreatic cancer CAN04 in combination with gem/abraxane in 1st line : • Durable responses observed (median DOR 6.8 mo, 27% response rate) • Important finding of pseudoprogression-like response in 5 (15%) patients predicting long PFS. • Promising PFS (7.8 mo) and OS (12.6 mo, 42 % e
Slide 14: Patients with Pseudoprogression-like response
Patients with Pseudoprogression-like response Subject 1 Subject 2 • All presented PD at 1st CT scan evaluation (8 weeks) • All showed concomitant Ongoing reduction of CA19-9 Subject 3 Subject 4 Subject 5 Ongoing PSEUDOPROGRESSION VERY UNCOMMON IN PANCREATIC CANCER INDICATE IMMUNE RELATED MECHANISM O
Slide 15: CAN04/GN in PDAC safety summary and benchmark
CAN04/GN in PDAC safety summary and benchmark Gem/Abraxane CANFOUR FOLFIRINOX Grade 3 or higher AEs (von Hoff) CAN04/GN (Conroy 2011) The beneficial effect in N=421 N=36 N=171 fatigue and chemotherapy- Neutropenia 38% 67% 46% induced neuropathy2 (nab- paclitaxel or oxaliplatin) Febrile neut
Slide 16: III. Untapped possibilities in autoimmune diseases
III. UNTAPPED POSSIBILITIES IN AUTOIMMUNE DISEASES
Slide 17: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in different mouse models (myocarditis, psoriasis, inflammation) → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease
Slide 18: mCAN10 improves heart function in experimental autoimmune myocarditis
mCAN10 improves heart function in experimental autoimmune myocarditis STRONG SUPPORT FOR SELECTION OF DEVELOPMENT STRATEGY 11
Slide 19: IV. Milestones and summary
IV. MILESTONES AND SUMMARY
Slide 20: Nadunolimab clinical development status
Nadunolimab clinical development status ClinicalTrials.gov Study Disease Combination therapy Status ID Updated interim results presented at NSCLC Cisplatin/gemcitabine ESMO in Q3 2021 Non-squamous Recruitment expected to start in CANFOUR NSCLC Carboplatin/pemetrexed Q4 2021 NCT03267316 Gemcitabine/n
Slide 21: Cantargia reached several milestones and have several value inflection points in near future
Cantargia reached several milestones and have several value inflection points in near future Newsflow over next 6 months Nadunolimab (CAN04) → New results PDAC, NSCLC and Keytruda combination → Randomized trials PDAC and NSCLC → New preclinical and translational results → New clinical trials • CAPAF
Slide 22: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors • Positive interim data set and further clinical milestones during 2021 VISION OF BECOMING AN IMPORTANT PART IN FUTURE CANCER TREATMENTS • Combinatio